hVIVO (LON:HVO) Shares Up 23% - What's Next?

hVIVO plc (LON:HVO - Get Free Report) shares shot up 23% during mid-day trading on Monday . The company traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). 24,253,932 shares traded hands during trading, an increase of 569% from the average session volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Wall Street Analysts Forecast Growth

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.

hVIVO Price Performance

The firm has a market capitalization of £76.07 million, a P/E ratio of 4.43 and a beta of 0.97. The business's 50-day simple moving average is GBX 15.92 and its 200 day simple moving average is GBX 17.70. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Sell-side analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.